Form 8-K Biofrontera Inc. For: Jun 11

Wed, 17 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260617/26659832.html

Form 8-K Biofrontera Inc. For: Jun 11

Wed, 17 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260617/26659832.html

Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

Thu, 21 May 2026 09:15:00 -0400

WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026.

Company Webcast

The webcast presentation will take place at 11:00 a.m. ET on Thursday, May 28, 2026. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/spring2026/ or directly at

Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

Thu, 21 May 2026 09:15:00 -0400

Company Webcast

Benchmark Downgrades Biofrontera (BFRI) to Speculative Buy

Tue, 19 May 2026 08:01:58 -0400

(Updated - May 19, 2026 8:01 AM EDT)

Benchmark analyst Bruce Jackson downgraded Biofrontera (NASDAQ: BFRI) from Buy to Speculative Buy with a price target of $3.00.

The analyst comments "Biofrontera reported in line 1Q results and reiterated its plans to break even on an operating cash flow basis for 2026, driven by a combination of accelerating revenue growth, lower cost of goods due to the renegotiated relationship with Biofrontera AG, and disciplined expense management. Management expects revenue growth to accelerate into 2027 as new labelling indications for superficial Basal Cell Carcinoma (sBCC) and extremities expand the potential market for Ameluz. Upcoming

Benchmark Downgrades Biofrontera (BFRI) to Speculative Buy

Tue, 19 May 2026 08:01:58 -0400

(Updated - May 19, 2026 8:01 AM EDT)

Benchmark analyst Bruce Jackson downgraded Biofrontera (NASDAQ: BFRI) from Buy to Speculative Buy with a price target of $3.00.

Form 10-Q Biofrontera Inc. For: Mar 31

Thu, 14 May 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260514/26495603.html

Form 10-Q Biofrontera Inc. For: Mar 31

Thu, 14 May 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260514/26495603.html

Biofrontera Inc. (BFRI) Misses Q1 EPS by 41c

Thu, 14 May 2026 15:53:53 -0400

Biofrontera Inc. (NASDAQ: BFRI) reported Q1 EPS of ($0.41). Revenue for the quarter came in at $10.1 million.

For earnings history and earnings-related data on Biofrontera Inc. (BFRI) click here.

Form 8-K Biofrontera Inc. For: May 14

Thu, 14 May 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260514/26490341.html

Form 8-K Biofrontera Inc. For: May 14

Thu, 14 May 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260514/26490341.html

Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update

Thu, 14 May 2026 07:30:00 -0400

Woburn, MA, May 14, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three months ended March 31, 2026 and provided a business update.

First Quarter Financial Highlights

Revenues for Q1 2026 were $10.1 million, a ~17% increase compared to $8.6 million for the same period in 2025.
Gross margins were about 80%, an 18 percentage points increase compared to approximately 62% in Q1 2025, reflecting the first full quarter under

Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update

Thu, 14 May 2026 07:30:00 -0400

First Quarter Financial Highlights

Revenues for Q1 2026 were $10.1 million, a ~17% increase compared to $8.6 million for the same period in 2025.
Gross margins were about 80%, an 18 percentage points increase compared to approximately 62% in Q1 2025, reflecting the first full quarter under

Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis